文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

非便秘型肠易激综合征的粪便短链脂肪酸：基于分解代谢分析的潜在临床相关分层因素。

Fecal short-chain fatty acids in non-constipated irritable bowel syndrome: a potential clinically relevant stratification factor based on catabotyping analysis.

机构信息

Department of Food, Environmental and Nutritional Sciences (DeFENS), University of Milan, Milan, Italy.

Dipartimento di Scienze Mediche e Chirurgiche, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

出版信息

Gut Microbes. 2023 Dec;15(2):2274128. doi: 10.1080/19490976.2023.2274128. Epub 2023 Nov 1.

DOI:10.1080/19490976.2023.2274128
PMID:37910479
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10773536/
Abstract

The gut microbiota is believed to be a critical factor in the pathogenesis of IBS, and its metabolic byproducts, such as short-chain fatty acids (SCFAs), are known to influence gut function and host health. Despite this, the precise role of SCFAs in IBS remains a topic of debate. In this study, we examined the bacterial community structure by 16S rRNA gene profiling and SCFA levels by UPLC-MS/MS in fecal samples from healthy controls (HC;  = 100) and non-constipated patients (IBS-D and IBS-M; NC-IBS;  = 240) enrolled in 19 hospitals in Italy. Our findings suggest a significant difference between the fecal microbiomes of NC-IBS patients and HC subjects, with HC exhibiting higher intra-sample biodiversity. Furthermore, we were able to classify non-constipated patients into two distinct subgroups based on their fecal SCFA levels (fecal catabotype "high" and "low"), each characterized by unique taxonomic bacterial signatures. Our results suggest that the fecal catabotype with higher SCFA levels may represent a distinct clinical phenotype of IBS that could have implications for its diagnosis and treatment. This study provides a new perspective on the intricate relationship between the gut microbiome and bowel symptoms in IBS, underscoring the importance of personalized strategies for its management.

摘要

肠道微生物群被认为是 IBS 发病机制的关键因素，其代谢产物，如短链脂肪酸（SCFAs），已知会影响肠道功能和宿主健康。尽管如此，SCFAs 在 IBS 中的确切作用仍然是一个争论的话题。在这项研究中，我们通过 16S rRNA 基因谱分析和 UPLC-MS/MS 检测粪便样本中的 SCFA 水平，检查了健康对照组（HC；= 100）和非便秘患者（IBS-D 和 IBS-M；NC-IBS；= 240）的细菌群落结构。我们的研究结果表明，NC-IBS 患者和 HC 受试者的粪便微生物群之间存在显著差异，HC 表现出更高的样本内生物多样性。此外，我们能够根据粪便 SCFA 水平将非便秘患者分为两个不同的亚组（粪便分解代谢型“高”和“低”），每个亚组都具有独特的分类细菌特征。我们的结果表明，具有更高 SCFA 水平的粪便分解代谢型可能代表 IBS 的一种独特的临床表型，这可能对其诊断和治疗具有重要意义。这项研究为 IBS 中肠道微生物群和肠道症状之间复杂的关系提供了一个新的视角，强调了针对其管理的个性化策略的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fea/10773536/a63a2a4f94f7/KGMI_A_2274128_F0009_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fea/10773536/d30eba824938/KGMI_A_2274128_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fea/10773536/c69a5065bbba/KGMI_A_2274128_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fea/10773536/4fac47c29c4b/KGMI_A_2274128_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fea/10773536/bbfc3afb275e/KGMI_A_2274128_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fea/10773536/cc3059345dd4/KGMI_A_2274128_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fea/10773536/2e30b0c543ad/KGMI_A_2274128_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fea/10773536/6ee617e7bd05/KGMI_A_2274128_F0007_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fea/10773536/44ce04d2b216/KGMI_A_2274128_F0008_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fea/10773536/a63a2a4f94f7/KGMI_A_2274128_F0009_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fea/10773536/d30eba824938/KGMI_A_2274128_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fea/10773536/c69a5065bbba/KGMI_A_2274128_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fea/10773536/4fac47c29c4b/KGMI_A_2274128_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fea/10773536/bbfc3afb275e/KGMI_A_2274128_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fea/10773536/cc3059345dd4/KGMI_A_2274128_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fea/10773536/2e30b0c543ad/KGMI_A_2274128_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fea/10773536/6ee617e7bd05/KGMI_A_2274128_F0007_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fea/10773536/44ce04d2b216/KGMI_A_2274128_F0008_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fea/10773536/a63a2a4f94f7/KGMI_A_2274128_F0009_OC.jpg

相似文献

[1]
Fecal short-chain fatty acids in non-constipated irritable bowel syndrome: a potential clinically relevant stratification factor based on catabotyping analysis.

Gut Microbes. 2023-12

[2]
Clinical response to fecal microbiota transplantation in patients with diarrhea-predominant irritable bowel syndrome is associated with normalization of fecal microbiota composition and short-chain fatty acid levels.

Scand J Gastroenterol. 2019-6

[3]
Sex-based differences in fecal short-chain fatty acid and gut microbiota in irritable bowel syndrome patients.

J Dig Dis. 2021-5

[4]
Omics profiles of fecal and oral microbiota change in irritable bowel syndrome patients with diarrhea and symptom exacerbation.

J Gastroenterol. 2022-10

[5]
Fecal Clostridiales distribution and short-chain fatty acids reflect bowel habits in irritable bowel syndrome.

Environ Microbiol. 2018-9-24

[6]
Characteristic dysbiosis of gut microbiota of Chinese patients with diarrhea-predominant irritable bowel syndrome by an insight into the pan-microbiome.

Chin Med J (Engl). 2019-4-20

[7]
[Effect of acupuncture therapy on gut microbiota and fecal short-chain fatty acids in patients with diarrhea type irritable bowel syndrome].

Zhongguo Zhen Jiu. 2021-2-12

[8]
Fecal bacteria and short-chain fatty acids in irritable bowel syndrome: Relations to subtype.

Neurogastroenterol Motil. 2024-9

[9]
Alterations in fecal short-chain fatty acids in patients with irritable bowel syndrome: A systematic review and meta-analysis.

Medicine (Baltimore). 2019-2

[10]
Gut fungal dysbiosis and altered bacterial-fungal interaction in patients with diarrhea-predominant irritable bowel syndrome: An explorative study.

Neurogastroenterol Motil. 2020-11

引用本文的文献

[1]
A bibliometric analysis of global research status and trends in irritable bowel syndrome and gut microbiota metabolites.

Front Microbiol. 2025-8-4

[2]
Multistrain Probiotics Plus Vitamin D Improve Gut Barrier Function and Gut Microbiota Composition in Irritable Bowel Syndrome Without Constipation: Results from a Double-Blind, Randomized, Placebo-Controlled Trial.

Nutrients. 2025-5-18

[3]
Synbiotic supplementation may globally improve non-motor symptoms in patients with stable Parkinson's disease: results from an open label single-arm study.

Sci Rep. 2024-10-4

[4]
Functional Abdominal Bloating and Gut Microbiota: An Update.

Microorganisms. 2024-8-14

[5]
Nitric oxide in the mechanisms of inhibitory effects of sodium butyrate on colon contractions in a mouse model of irritable bowel syndrome.

Naunyn Schmiedebergs Arch Pharmacol. 2025-2

[6]
Microbiome-driven IBS metabotypes influence response to the low FODMAP diet: insights from the faecal volatome.

EBioMedicine. 2024-9

[7]
Fecal Microbiota Characteristics in Constipation-Predominant and Mixed-Type Irritable Bowel Syndrome.

Microorganisms. 2024-7-12

本文引用的文献

[1]
Fecal microbiota transplantation for irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials.

Front Immunol. 2023

[2]
Irritable Bowel Syndrome and the Gut Microbiome: A Comprehensive Review.

J Clin Med. 2023-3-28

[3]
Effect of rapid colonic transit on stool microbiome and short-chain fatty acids in diarrhoea-predominant irritable bowel syndrome.

Gut. 2024-1-5

[4]
Multi-omics profiles of the intestinal microbiome in irritable bowel syndrome and its bowel habit subtypes.

Microbiome. 2023-1-10

[5]
Gut microbiome signatures reflect different subtypes of irritable bowel syndrome.

Gut Microbes. 2023

[6]
Randomised clinical trial: efficacy and safety of the live biotherapeutic product MRx1234 in patients with irritable bowel syndrome.

Aliment Pharmacol Ther. 2023-1

[7]
The Role of Short Chain Fatty Acids in Irritable Bowel Syndrome.

J Neurogastroenterol Motil. 2022-10-30

[8]
Omics profiles of fecal and oral microbiota change in irritable bowel syndrome patients with diarrhea and symptom exacerbation.

J Gastroenterol. 2022-10

[9]
Fecal Microbiota Signatures Are Not Consistently Related to Symptom Severity in Irritable Bowel Syndrome.

Dig Dis Sci. 2022-11

[10]
Intestinal Microbiota-Derived Short Chain Fatty Acids in Host Health and Disease.

Nutrients. 2022-5-9

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索